CoChat
Sign Up
Cited by 102

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

New insights into p53 activation

Brooks, Christopher L, Gu, Wei·2010·Cell Research
DOI 10.1038/cr.2010.53PMC PMC3070262
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/cr.2010.53

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 26 references

Research works printed but not linked: 64

  1. Bensaad K, Vousden KH . p53: new roles in metabolism. Trends Cell Biol 2007; 17:286–291. · DOI
  2. Vousden KH, Lane DP . p53 in health and disease. Nat Rev Mol Cell Biol 2007; 8:275–283. · DOI
  3. Kruse JP, Gu W . SnapShot: p53 posttranslational modifications. Cell 2008; 133:930–930.e1. · DOI
  4. Brooks CL, Gu W . p53 ubiquitination: Mdm2 and beyond. Mol Cell 2006; 21:307–315. · DOI · Paper page
  5. Mayo LD, Donner DB . The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem Sci 2002; 27:462–467. · DOI
  6. Meek DW . The p53 response to DNA damage. DNA Repair (Amst) 2004; 3:1049–1056. · DOI · Paper page
  7. Teufel DP, Bycroft M, Fersht AR . Regulation by phosphorylation of the relative affinities of the N-terminal transactivation domains of p53 for p300 domains and Mdm2. Oncogene 2009; 28:2112–2118. · DOI
  8. Appella E, Anderson CW . Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem 2001; 268:2764–2772. · DOI
  9. Sluss HK, Armata H, Gallant J, Jones SN . Phosphorylation of serine 18 regulates distinct p53 functions in mice. Mol Cell Biol 2004; 24:976–984. · DOI · Paper page
  10. Chao C, Herr D, Chun J, Xu Y . Ser18 and 23 phosphorylation is required for p53-dependent apoptosis and tumor suppression. EMBO J 2006; 25:2615–2622.
  11. Wu Z, Earle J, Saito S, et al. Mutation of mouse p53 Ser23 and the response to DNA damage. Mol Cell Biol 2002; 22:2441–2449. · DOI · Paper page
  12. Ashcroft M, Kubbutat MH, Vousden KH . Regulation of p53 function and stability by phosphorylation. Mol Cell Biol 1999; 19:1751–1758. · DOI · Paper page
  13. Ashcroft M, Taya Y, Vousden KH . Stress signals utilize multiple pathways to stabilize p53. Mol Cell Biol 2000; 20:3224–3233. · DOI
  14. Blattner C, Tobiasch E, Litfen M, Rahmsdorf HJ, Herrlich P . DNA damage induced p53 stabilization: no indication for an involvement of p53 phosphorylation. Oncogene 1999; 18:1723–1732. · DOI · Paper page
  15. Wang X, Taplick J, Geva N, Oren M . Inhibition of p53 degradation by Mdm2 acetylation. FEBS Lett 2004; 561:195–201. · DOI
  16. Tang Y, Zhao W, Chen Y, Zhao Y, Gu W . Acetylation is indispensable for p53 activation. Cell 2008; 133:612–626. · DOI · Paper page
  17. Ito A, Lai CH, Zhao X, et al. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J 2001; 20:1331–1340. · DOI
  18. Li M, Luo J, Brooks CL, Gu W . Acetylation of p53 inhibits its ubiquitination by Mdm2. J Biol Chem 2002; 277:50607–50611. · DOI · Paper page
  19. Feng L, Lin T, Uranishi H, Gu W, Xu Y . Functional analysis of the roles of posttranslational modifications at the p53 C terminus in regulating p53 stability and activity. Mol Cell Biol 2005; 25:5389–5395. · DOI · Paper page
  20. Krummel KA, Lee CJ, Toledo F, Wahl GM . The C-terminal lysines fine-tune P53 stress responses in a mouse model but are not required for stability control or transactivation. Proc Natl Acad Sci USA 2005; 102:10188–10193. · DOI · Paper page
  21. Chan WM, Mak MC, Fung TK, et al. Ubiquitination of p53 at multiple sites in the DNA-binding domain. Mol Cancer Res 2006; 4:15–25. · DOI
  22. Chen D, Kon N, Li M, et al. ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell 2005; 121:1071–1083. · DOI
  23. Dornan D, Wertz I, Shimizu H, et al. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 2004; 429:86–92. · DOI
  24. Kruse JP, Gu W . MSL2 promotes Mdm2-independent cytoplasmic localization of p53. J Biol Chem 2009; 284:3250–3263. · DOI
  25. Leng RP, Lin Y, Ma W, et al. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 2003; 112:779–791. · DOI
  26. Sheng Y, Laister RC, Lemak A, et al. Molecular basis of Pirh2-mediated p53 ubiquitylation. Nat Struct Mol Biol 2008; 15:1334–1342. · DOI
  27. Sherr CJ . Divorcing ARF and p53: an unsettled case. Nat Rev Cancer 2006; 6:663–673. · DOI · Paper page
  28. Weber JD, Taylor LJ, Roussel MF, Sherr CJ, Bar-Sagi D . Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol 1999; 1:20–26. · DOI · Paper page
  29. Llanos S, Clark PA, Rowe J, Peters G . Stabilization of p53 by p14ARF without relocation of MDM2 to the nucleolus. Nat Cell Biol 2001; 3:445–452. · DOI
  30. Fang S, Jensen JP, Ludwig RL, Vousden KH, Weissman AM . Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem 2000; 275:8945–8951. · DOI · Paper page
  31. Itahana K, Mao H, Jin A, et al. Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer Cell 2007; 12:355–366. · DOI · Paper page
  32. Brooks CL, Li M, Hu M, Shi Y, Gu W . The p53--Mdm2--HAUSP complex is involved in p53 stabilization by HAUSP. Oncogene 2007; 26:7262–7266. · DOI
  33. Li M, Chen D, Shiloh A, et al. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 2002; 416:648–653. · DOI
  34. Song MS, Song SJ, Kim SY, Oh HJ, Lim DS . The tumour suppressor RASSF1A promotes MDM2 self-ubiquitination by disrupting the MDM2-DAXX-HAUSP complex. EMBOJ 2008; 27:1863–1874. · DOI
  35. Tang J, Qu LK, Zhang J, et al. Critical role for Daxx in regulating Mdm2. Nat Cell Biol 2006; 8:855–862. · DOI
  36. Li M, Brooks CL, Kon N, Gu W . A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol Cell 2004; 13:879–886. · DOI · Paper page
  37. Brown JP, Wei W, Sedivy JM . Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts. Science 1997; 277:831–834. · DOI · Paper page
  38. Michalak EM, Villunger A, Adams JM, Strasser A . In several cell types tumour suppressor p53 induces apoptosis largely via Puma but Noxa can contribute. Cell Death Differ 2008; 15:1019–1029. · DOI
  39. Yu J, Zhang L . No PUMA, no death: implications for p53-dependent apoptosis. Cancer Cell 2003; 4:248–249. · DOI
  40. el-Deiry WS . Regulation of p53 downstream genes. Semin Cancer Biol 1998; 8:345–357. · DOI
  41. Yu J, Zhang L . The transcriptional targets of p53 in apoptosis control. Biochem Biophys Res Commun 2005; 331:851–858. · DOI
  42. He L, He X, Lowe SW, Hannon GJ . microRNAs join the p53 network--another piece in the tumour-suppression puzzle. Nat Rev Cancer 2007; 7:819–822. · DOI
  43. Halazonetis TD, Gorgoulis VG, Bartek J . An oncogene-induced DNA damage model for cancer development. Science 2008; 319:1352–1355. · DOI · Paper page
  44. Leal JF, Fominaya J, Cascon A, et al. Cellular senescence bypass screen identifies new putative tumor suppressor genes. Oncogene 2008; 27:1961–1970. · DOI
  45. Barboza JA, Liu G, Ju Z, El-Naggar AK, Lozano G . p21 delays tumor onset by preservation of chromosomal stability. Proc Natl Acad Sci USA 2006; 103:19842–19847. · DOI
  46. Bordone L, Guarente L . Calorie restriction, SIRT1 and metabolism: understanding longevity. Nat Rev Mol Cell Biol 2005; 6:298–305. · DOI
  47. Brooks CL, Gu W . How does SIRT1 affect metabolism, senescence and cancer? Nat Rev Cancer 2009; 9:123–128. · DOI
  48. Barboza JA, Iwakuma T, Terzian T, El-Naggar AK, Lozano G . Mdm2 and Mdm4 loss regulates distinct p53 activities. Mol Cancer Res 2008; 6:947–954. · DOI
  49. Marine JC, Jochemsen AG . Mdmx and Mdm2: brothers in arms? Cell Cycle 2004; 3:900–904. · DOI
  50. Marine JC, Jochemsen AG . Mdmx as an essential regulator of p53 activity. Biochem Biophys Res Commun 2005; 331:750–760. · DOI
  51. Ohkubo S, Tanaka T, Taya Y, Kitazato K, Prives C . Excess HDM2 impacts cell cycle and apoptosis and has a selective effect on p53-dependent transcription. J Biol Chem 2006; 281:16943–16950. · DOI
  52. Iwakuma T, Lozano G . Crippling p53 activities via knock-in mutations in mouse models. Oncogene 2007; 26:2177–2184. · DOI
  53. Wahl GM . Mouse bites dogma: how mouse models are changing our views of how P53 is regulated in vivo. Cell Death Differ 2006; 13:973–983. · DOI
  54. Migliorini D, Lazzerini Denchi E, Danovi D, et al. Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. Mol Cell Biol 2002; 22:5527–5538. · DOI · Paper page
  55. Johnson TM, Hammond EM, Giaccia A, Attardi LD . The p53QS transactivation-deficient mutant shows stress-specific apoptotic activity and induces embryonic lethality. Nat Genet 2005; 37:145–152. · DOI
  56. Shaked H, Shiff I, Kott-Gutkowski M, et al. Chromatin immunoprecipitation-on-chip reveals stress-dependent p53 occupancy in primary normal cells but not in established cell lines. Cancer Res 2008; 68:9671–9677. · DOI
  57. Caron de Fromentel C, Soussi T . TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosomes Cancer 1992; 4:1–15. · DOI
  58. Greenblatt MS, Bennett WP, Hollstein M, Harris CC . Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54:4855–4878.
  59. Hainaut P, Hollstein M . p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 2000; 77:81–137. · DOI
  60. Hollstein M, Sidransky D, Vogelstein B, Harris CC . p53 mutations in human cancers. Science 1991; 253:49–53. · DOI · Paper page
  61. Toledo F, Wahl GM . Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 2006; 6:909–923. · DOI · Paper page
  62. Issaeva N, Bozko P, Enge M, et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 2004; 10:1321–1328. · DOI
  63. Yang Y, Ludwig RL, Jensen JP, et al. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 2005; 7:547–559. · DOI
  64. Lain S, Hollick JJ, Campbell J, et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 2008; 13:454–463. · DOI

Cited by

Sorted by citations

See all 102

Metadata

Authors
Brooks, C. L., & Gu, W.
Venue
Cell Research
Publisher
Springer Science and Business Media LLC
Published
2010-04-20
Volume
20
Issue
6
Pages
614-621
ISSN
  • 1001-0602
  • 1748-7838
DOI
10.1038/cr.2010.53
PMC
PMC3070262
Cited by
102
References
26
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review